{
    "2020-05-08": [
        [
            {
                "time": "2023-10-01",
                "original_text": "复星医药(600196.SH)：FCN-338片用于血液系统恶性肿瘤治疗药品临床试验申请获受理",
                "features": {
                    "keywords": [
                        "复星医药",
                        "FCN-338",
                        "临床试验",
                        "血液系统恶性肿瘤"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "药企频现离职潮 是薪酬太少还是行业变局倒逼",
                "features": {
                    "keywords": [
                        "药企",
                        "离职潮",
                        "薪酬",
                        "行业变局"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "复星医药(600196.SH)：汉霖生技获药品临床试验批准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "汉霖生技",
                        "临床试验",
                        "药品"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "传复星前全球合伙人兼CTO梁剑峰加盟中梁控股",
                "features": {
                    "keywords": [
                        "复星",
                        "梁剑峰",
                        "中梁控股",
                        "CTO"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "多元化企业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "新冠病毒检测试剂市场放量 相关公司二季度业绩受益",
                "features": {
                    "keywords": [
                        "新冠病毒",
                        "检测试剂",
                        "市场放量",
                        "二季度业绩"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "[公司]智慧物流带动全年业务 药物研发外包行业有望带动迦南科技新突破",
                "features": {
                    "keywords": [
                        "智慧物流",
                        "药物研发外包",
                        "迦南科技",
                        "新突破"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "物流",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "QFII投资风格大复盘，高比例持股组合年均复合收益率近20%！目前重仓这些股",
                "features": {
                    "keywords": [
                        "QFII",
                        "投资风格",
                        "年均复合收益率",
                        "重仓股"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "投资"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}